Invitation to presentation of Essity's Year-end Report for 2020
STOCKHOLM, Dec. 18, 2020 /PRNewswire/ -- Essity's Year-end Report for 2020 will be published on January 27 at approximately 7:00 CET. In conjunction with publication, a telephone and web presentation will be held at 9:00 CET where President and CEO Magnus Groth will present and answer questions.
Telephone: +44 (0) 207 192 80 00, + 1 631 510 74 95 or +46 (0) 8 506 921 80. Please call in well in advance of the start of the presentation. Indicate "Essity" or conference ID 7569943.
For further information, please contact:
Per Lorentz, Vice President Corporate Communications, +46 8 788 52 51, [email protected]
Johan Karlsson, Vice President Investor Relations, +46 8 788 51 30, [email protected]
Merck , known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved KEYTRUDA, Merck's anti-PD-1 therapy, in combination with platinum-containing chemotherapy as neoadjuvant treatment, then...
Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its annual...
Caris Life Sciences®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular...
The collagen water market is booming thanks to the growing popularity of health and beauty products. Consumers are more interested in skincare and healthy eating, which is driving manufacturers to create collagen-infused drinks and cosmetics. A new...
Viavi Solutions Inc. (VIAVI) today announced it has participated in the 2024 RIC Forum, March 26-28, in Dallas, Texas. The company contributed its TeraVM RIC Test and TM500 Network Tester to multiple demonstrations, building on collaborations at MWC...
Three clinical programs present diversified opportunities in and outside the existing anti-VEGF market and are being progressed toward Phase 3 value inflection points New Phase 3 GLOW2 study of tarcocimab in diabetic retinopathy actively...